Context Therapeutics Inc. announced on January 14, 2025, that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76. CTIM-76 is a Claudin 6 (CLDN6) x CD3 T cell engaging bispecific antibody.
The Phase 1 dose escalation and expansion trial is enrolling patients with CLDN6-positive gynecologic and testicular cancers. This trial marks a key advancement of Context's clinical pipeline, moving CTIM-76 into human testing.
The company anticipates sharing initial data for the CTIM-76 Phase 1 trial in the first half of 2026. The study is expected to enroll up to 70 patients to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.